TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1325319

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (2 pmol min‐1 kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (saline, 150 mmol/l NaCl)
Number of subjects: 6
Study: 6380466

Group type: EXPERIMENTAL
Intervention: Regular drops of 0.25% clonidine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Regular drops of 0.50% clonidine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Minidrops of 0.25% clonidine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Minidrops of 0.50% clonidine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (0% clonidine)
Number of subjects: 16
Study: 29912429

Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 6 L/min for 6-12 hours
Number of subjects: 2807

Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 2807

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 2807
Study: 26159803

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24799602

Group type: EXPERIMENTAL
Intervention: Low 25(OH)D levels (<32 ng/mL)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Baseline low 25(OH)D
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: WHO stage 3/4 disease or death within 96 weeks of cART initiation
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Virologic failure
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Immunologic failure
Number of subjects: 411
Study: 23306096

Group type: EXPERIMENTAL
Intervention: Doxazosin (8mg/day) - DOX-fast group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Doxazosin (8mg/day) - DOX-slow group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 20424590

Group type: EXPERIMENTAL
Intervention: Real 1 Hz rTMS
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 52
Study: 17922525

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 8214

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 8214
Study: 16824243

Group type: EXPERIMENTAL
Intervention: Thoracic epidural infusion of 0.2% ropivacaine (group EPI, n = 21)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Paravertebral infusion of 0.2% ropivacaine (group PVB, n = 21)
Number of subjects: 42
Study: 12796858

Group type: EXPERIMENTAL
Intervention: Music-reinforced nonnutritive sucking intervention (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No-contact control group (n = 16)
Number of subjects: 32
Study: 10993126

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 778

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 778
Study: 9191873

Group type: EXPERIMENTAL
Intervention: OK-432 (picibanil) administered ID twice weekly for 3 months at dosages ranging from 1 KE to 20 KE
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: OK-432 (picibanil) administered ID twice weekly for 3 months
Number of subjects: 48
Study: 7693476

Group type: EXPERIMENTAL
Intervention: Nutrizym 22 (double strength)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nutrizym GR (standard preparation)
Number of subjects: 25
Study: 3963089

Group type: EXPERIMENTAL
Intervention: bromocriptine mesylate (Parlodel)
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 28639554

Group type: EXPERIMENTAL
Intervention: Procalcitonin levels in group A
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: hs-CRP levels in group A
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Procalcitonin levels in patients with low-frequency hearing loss
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ROC analysis of procalcitonin values
Number of subjects: 23

Group type: COMPARATOR
Intervention: Procalcitonin levels in group B
Number of subjects: 23

Group type: COMPARATOR
Intervention: hs-CRP levels in group B
Number of subjects: 23
Study: 26509361

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (median dose = 800 mcg)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Number of subjects: 130
Study: 25370587

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg/kg) plus standard care
Number of subjects: 3035

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 3035
Study: 23782845

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine/70% isopropyl alcohol
Number of subjects: 2400

Group type: COMPARATOR
Intervention: 5% povidone iodine/69% ethanol
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Enhanced skin cleaning prior to disinfection
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Comparison of skin colonization at catheter insertion site
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Comparison of catheter colonization and catheter-related bacteremia
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Cutaneous tolerance
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Costs
Number of subjects: 2400
Study: 21118175

Group type: EXPERIMENTAL
Intervention: Combination therapy of bisoprolol and ivabradine (mean dose 10.7±3.1 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination therapy of bisoprolol and ivabradine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bisoprolol alone
Number of subjects: 50
Study: 18375472

Group type: EXPERIMENTAL
Intervention: Left atrial epicardial radiofrequency (RF) ablation
Number of subjects: 39

Group type: COMPARATOR
Intervention: No ablation
Number of subjects: 39
Study: 16603801

Group type: EXPERIMENTAL
Intervention: Cumulative sums (cusums) method using interval blood pressure values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative sums (cusums) method with altered CPS time by 1 hour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative sums (cusums) method with hourly readings
Number of subjects: 0
Study: 10979639

Group type: EXPERIMENTAL
Intervention: Tiklid
Number of subjects: 54

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 54
Study: 8839318

Group type: EXPERIMENTAL
Intervention: Survey items on HIV-related behaviors with anonymity
Number of subjects: 291

Group type: COMPARATOR
Intervention: Survey items on HIV-related behaviors without anonymity
Number of subjects: 291
Study: 1442344

Group type: EXPERIMENTAL
Intervention: Steroid regimen A (7 weeks duration)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Steroid regimen B (15 weeks duration)
Number of subjects: 54
Study: 3982468

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (4000 U per minute, total of 286,000 +/- 77,800 U over 72 +/- 24 minutes)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase with successful reperfusion
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Partial reperfusion
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: No reperfusion
Number of subjects: 250
Study: 31874985

Group type: EXPERIMENTAL
Intervention: treatment cream
Number of subjects: 31

Group type: COMPARATOR
Intervention: control cream
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: anticipatory treatment cues
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: placebo responders
Number of subjects: 31
Study: 29484257

Group type: COMPARATOR
Intervention: Cathodal HD-tDCS (1.5-mA, 20-min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anodal HD-tDCS (1.5-mA, 20-min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 0
Study: 26111957

Group type: EXPERIMENTAL
Intervention: palonosetron (0.25, 0.75, or 2.25 mg)
Number of subjects: 221

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: moxifloxacin (400 mg)
Number of subjects: 221
Study: 24621778

Group type: EXPERIMENTAL
Intervention: Sitagliptin in combination with CSII therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: CSII monotherapy
Number of subjects: 80
Study: 22966009

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Hypertensive participants
Number of subjects: 723
Study: 20451686

Group type: EXPERIMENTAL
Intervention: P‐OM3 4 g/day
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 17926090

Group type: EXPERIMENTAL
Intervention: Lipiodol-ethanol mixture (LEM; Group A)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lipiodol alone (Group B)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lipiodol and gelatin pledgets (Group C)
Number of subjects: 13
Study: 19818685

Group type: COMPARATOR
Intervention: Fluorouracil (800 mg/m2 per day, days 1-5, every 4 weeks)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (irinotecan 70 mg/m2 on days 1 and 15, cisplatin 80 mg/m2 on day 1, every 4 weeks)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: S-1 (40 mg/m2 twice a day, days 1-28, every 6 weeks)
Number of subjects: 704
Study: 15229770

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 1151
Study: 11697841

Group type: EXPERIMENTAL
Intervention: Docetaxel at 100 mg/m2 every three weeks (with a switch to 40 mg/m2 weekly in case of severe toxicity)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Docetaxel (reinduction after progression)
Number of subjects: 27
Study: 9596428

Group type: EXPERIMENTAL
Intervention: 120 mg pseudoephedrine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: oxymetazoline nasal spray (0.05%)
Number of subjects: 150

Group type: COMPARATOR
Intervention: double placebo (capsule and nasal spray)
Number of subjects: 150
Study: 7869015

Group type: EXPERIMENTAL
Intervention: Monospecific antivenin therapy (60 ml administered intravenously at 6-hour intervals until blood coagulability is restored)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monospecific antivenin therapy
Number of subjects: 30
Study: 3215145

Group type: EXPERIMENTAL
Intervention: Low dose T3 administration (25 micrograms per day for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study: 31801608

Group type: EXPERIMENTAL
Intervention: Bipolar disorder group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 10
Study: 28796588

Group type: EXPERIMENTAL
Intervention: G-CHOP (Obinutuzumab plus CHOP)
Number of subjects: 1418

Group type: COMPARATOR
Intervention: R-CHOP (Rituximab plus CHOP)
Number of subjects: 1418

Group type: EXPERIMENTAL
Intervention: G-CHOP
Number of subjects: 1418

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 1418
Study: 26332503

Group type: EXPERIMENTAL
Intervention: ERSPC-RC (DRE-based version 3/4)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: PCPT-RC (version 2.0)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: ERSPC-RC
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: PCPT-RC
Number of subjects: 1996
Study: 24951296

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (70 mL) consumed 150 min before the first time trial
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (70 mL) consumed 75 min before the first time trial
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (35 mL top-up dose) after the first time trial
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22329822

Group type: EXPERIMENTAL
Intervention: Outreach (community-based victim advocate outreach)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Referral (criminal justice system-based victim advocate referrals to community-based agencies)
Number of subjects: 236
Study: 19744307

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine and cytotoxic therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anthracyclines and taxanes
Number of subjects: 0
Study: 17563979

Group type: EXPERIMENTAL
Intervention: Mud applications at 38-40 degrees C for AS patients with prevalent spinal lesions
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mud applications at 22-24 degrees C for AS patients with prevalent joint lesions
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mud applications at 38-40 degrees C for AS patients free of inflammation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mud applications at 22-24 degrees C for patients with reactive arthritis and Reiter's disease
Number of subjects: 71
Study: 16244017

Group type: EXPERIMENTAL
Intervention: Intraoperative IV ondansetron (4 mg) followed by postoperative ondansetron (8 mg BID for up to 72 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12107603

Group type: EXPERIMENTAL
Intervention: Digitoxin (0.6 mg day 1, 0.4 mg day 2, then 0.1 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10460216

Group type: EXPERIMENTAL
Intervention: PvuII polymorphism
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study: 7598300

Group type: EXPERIMENTAL
Intervention: K‐ras gene analysis in patients with pancreatic cancer (group 3)
Number of subjects: 75

Group type: COMPARATOR
Intervention: K‐ras gene analysis in patients with no pancreatic disease (group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: K‐ras gene analysis in patients with nontumoral pancreatic disease (group 2)
Number of subjects: 75
Study: 2121070

Group type: EXPERIMENTAL
Intervention: Chlorhexidine dressing (CHX dressing)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standardized dressing (Control)
Number of subjects: 57
Study: 365851

Group type: EXPERIMENTAL
Intervention: Ingestion of artificial food colors
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Challenge effects
Number of subjects: 2
Study: 30929657

Group type: EXPERIMENTAL
Intervention: Major Depression (MD)
Number of subjects: 135458

Group type: EXPERIMENTAL
Intervention: Alcohol Consumption (AC) - Quantity
Number of subjects: 135458

Group type: EXPERIMENTAL
Intervention: Alcohol Consumption (AC) - Frequency
Number of subjects: 135458
Study: 27741367

Group type: EXPERIMENTAL
Intervention: Investigational cigarette with 0.4 mg/g nicotine content
Number of subjects: 839
Study: 24993569

Group type: EXPERIMENTAL
Intervention: Transtibial single-bundle (SB) ACL reconstruction
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Anatomic SB ACL reconstruction
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: KT-1000 knee laxity measurements
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: KOOS and IKDC subjective outcome scores
Number of subjects: 47
Study: 24113764

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet‐based maintenance treatment (TIMT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment-as-usual control condition
Number of subjects: 400
Study: 21835552

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Post-discharge behavioral treatment
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Re-hospitalization
Number of subjects: 79
Study: 19271826

Group type: EXPERIMENTAL
Intervention: Florida's Family Transition Program (FTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (comparable group of single-mother welfare-recipient families)
Number of subjects: 0
Study: 17676252

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 3870

Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 3870

Group type: EXPERIMENTAL
Intervention: Illicit drug use
Number of subjects: 3870
Study: 15161945

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 107
Study: 11252284

Group type: EXPERIMENTAL
Intervention: Social-behavioral curricula in schools, peer leadership activities, parental involvement and education, community-wide activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy to refuse offers of alcohol among those who did not use alcohol at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer influence to use, including normative estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional meanings of alcohol use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attitudes and behaviors associated with alcohol and drug problems like stimulus seeking, rule violations and bad judgement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent-child alcohol-related communication around alcohol use
Number of subjects: 0
Study: 9552137

Group type: EXPERIMENTAL
Intervention: DHAGF: 0.3 wt% docosahexaenoic acid and 0.5 wt% gamma‐linolenic acid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: DHAF: 0.3 wt% docosahexaenoic acid
Number of subjects: 37

Group type: COMPARATOR
Intervention: STF: standard formula without long‐chain polyunsaturated fatty acids
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All formula-fed infants
Number of subjects: 37
Study: 8109762

Group type: EXPERIMENTAL
Intervention: Intrathecal 2.5 mg bupivacaine + 22.2 +/- 4.6 mL epidural lidocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal 5 mg bupivacaine + 10.1 +/- 2.0 mL epidural lidocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal 7.5 mg bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg bupivacaine
Number of subjects: 80
Study: 2842144

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.001, 0.003, 0.007 or 0.014 mg kg-1)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Flumazenil (3.0 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Flumazenil (1.0 mg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 31016502

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) or myocardial perfusion scintigraphy (MPS)
Number of subjects: 292
Study: 28174327

Group type: EXPERIMENTAL
Intervention: MRI-based thrombolysis
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Daytime unwitnessed stroke
Number of subjects: 1005
Study: 26261386

Group type: EXPERIMENTAL
Intervention: fluconazole 150 mg 1x weekly
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: itraconazole continual therapy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: itraconazole pulse therapy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: terbinafine 250 mg/d
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: terbinafine + ciclopirox 8% lacquer
Number of subjects: 133
Study: 23503447

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (n = 98)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted fosamprenavir (n = 69)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted saquinavir (n = 99)
Number of subjects: 275
Study: 21146259

Group type: EXPERIMENTAL
Intervention: Spirituality training for nurses
Number of subjects: 75
Study: 19555446

Group type: EXPERIMENTAL
Intervention: Prebiotic mixture (0.8 g/dL of scGOS and lcFOS, ratio 9:1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Maltodextrines (placebo)
Number of subjects: 76
Study: 16905065

Group type: COMPARATOR
Intervention: RME-only
Number of subjects: 66

Group type: COMPARATOR
Intervention: RME-Sz
Number of subjects: 66
Study: 14716693

Group type: EXPERIMENTAL
Intervention: Donepezil (2.5-10 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11729740

Group type: EXPERIMENTAL
Intervention: mf-ERG
Number of subjects: 24

Group type: COMPARATOR
Intervention: Full-field ERG
Number of subjects: 24
Study: 9709137

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope with modified cricoid pressure
Number of subjects: 100

Group type: COMPARATOR
Intervention: McCoy laryngoscope without modified cricoid pressure
Number of subjects: 100
Study: 8019022

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2660958

Group type: EXPERIMENTAL
Intervention: Ioversol-240 (MP-238)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Iothalamate-202 (Conray 43)
Number of subjects: 50
Study: 31077311

Group type: EXPERIMENTAL
Intervention: Cisplatin/gemcitabine chemotherapy
Number of subjects: 109
Study: 27432587

Group type: COMPARATOR
Intervention: Standard ablation system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma ablation system
Number of subjects: 0
Study: 25948767

Group type: EXPERIMENTAL
Intervention: High PUFA dietary supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (supplementation without PUFA)
Number of subjects: 0
Study: 23183442

Group type: EXPERIMENTAL
Intervention: Intramuscular quinine (loading dose of 20 mg quinine dihydrochloride/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intramuscular quinine
Number of subjects: 75
Study: 21451166

Group type: EXPERIMENTAL
Intervention: New upper bedding duck feather pillow and quilt with a mite-occlusive mattress cover
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard care with a mite-occlusive mattress cover
Number of subjects: 197
Study: 19116400

Group type: EXPERIMENTAL
Intervention: Transparent film dressing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adhesive bandage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pressure dressing
Number of subjects: 100
Study: 16448867

Group type: EXPERIMENTAL
Intervention: Methyldopa preparation 1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methyldopa preparation 2
Number of subjects: 24
Study: 14982261

Group type: EXPERIMENTAL
Intervention: 56-French Pilling dilators
Number of subjects: 30

Group type: COMPARATOR
Intervention: 40-French Pilling dilators (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (56-French and 40-French dilators)
Number of subjects: 30
Study: 12740337

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 660

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660